Skip to main content
Clinical Trials/NCT03876314
NCT03876314
Completed
Not Applicable

The Effect of Physical Activity on Cognition Relative to APOE Genotype (PAAD-2)

University of North Carolina, Greensboro1 site in 1 country180 target enrollmentMay 23, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy
Sponsor
University of North Carolina, Greensboro
Enrollment
180
Locations
1
Primary Endpoint
Change in performance on the cognitive domain of memory as measured with the Rey-Osterrieth Complex Figure Test
Status
Completed
Last Updated
last year

Overview

Brief Summary

Physical activity and Alzheimer's disease (PAAD-2) is a randomized control trial that will assess the effects of exercise on middle-aged (40-65 years) cognitively normal adults who have a heightened risk of Alzheimer's disease (AD) due to family history (FH+). The investigators will also assess the extent to which this effect is moderated by apolipoprotein epsilon-4 (APOE4) carrier status, and will gather critical new experimental evidence on the use of physical activity to improve cognitive performance by persons at the greatest risk of Alzheimer's disease.

Detailed Description

In this study, the investigators follow up on their past research exploring the effects of physical activity on cognitive performance and underlying mechanisms. In particular, the investigators are interested in the potentially different effects that might be realized as a function of a person's genetic risk for Alzheimer's disease. In this study, the investigators extend past work by proposing a randomized clinical trial to: (a) test the causal link between physical activity and cognitive performance in middle-aged adults (40-65 years) with a family history, and (b) determine if the effect is moderated by apolipoprotein epsilon-4 (APOE4) carrier status. The investigators will collect neuroimaging measures of cerebral structure, white matter integrity, and resting state connectivity; assess putative biological markers; and (using moderated mediation analyses) increase understanding of underlying mechanisms and of the extent to which effects are moderated by APOE4 carrier status. To test hypotheses, the investigators will randomly assign 240 cognitively normal, middle-aged adults to a 1-year virtual physical activity program or a usual care control. Those in the intervention will participate in a year-long physical activity program including aerobic exercise performed on your own and resistance exercises led in virtual exercise sessions with an instructor 1 hour/day for 3 days/week for 1 year. Those in the usual care control condition will be asked to maintain their normal lifestyle for one year and then will be given a short-term fitness center membership (contingent upon completion of testing sessions). The investigators will assess cognitive performance at pre-, mid-, and post-test, and obtain MRI scans and blood samples at pre-, mid- and post-test. The investigators will examine the effects of physical activity on cognitive performance and on neurological and biological mechanisms and will explore the moderating role of APOE4.

Registry
clinicaltrials.gov
Start Date
May 23, 2019
End Date
December 21, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University of North Carolina, Greensboro
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Family History of Alzheimer's disease, cognitive impairment
  • Able to communicate in English
  • Not currently meeting recommendations for physical activity (the recommendations are to exercise 3 days/week for 30+ minutes per day for longer than 3 months)
  • Willing to be randomized to either study condition
  • Willing to complete all study activities for 1 year

Exclusion Criteria

  • Meet the criteria for clinical cognitive impairment
  • Unable to perform physical activity due to known cardiovascular, metabolic, or renal disease and are symptomatic or due to orthopedic limitations
  • Self-report history of confounding neurologic, psychiatric, or active severe or functionally disabling neurologic or medical diseases, or any other conditions that might limit exercise or pose a danger to the patient
  • Current use of medications to treat symptoms of Alzheimer's disease, that adversely affect cognition, or that impact heart rate
  • Meet the criteria for depression using the short form of the Center for Epidemiological Studies Depression Scale
  • Traveling for an extended period (\>1 month) during the course of the study

Outcomes

Primary Outcomes

Change in performance on the cognitive domain of memory as measured with the Rey-Osterrieth Complex Figure Test

Time Frame: Pretest, 6 months, and 12 months

Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Rey-Osterrieth Complex Figure Test

Change in performance on the cognitive domain of memory as measured with the Mnemonic Similarity Test

Time Frame: Pretest, 6 months, and 12 months

Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Mnemonic Similarity Test

Change in performance on the cognitive domain of attention as measured with the Paced Auditory Serial Addition Test

Time Frame: Pretest, 6 months, and 12 months

Change in attention will be assessed by comparing post-, mid-, and pre-test performance on the Paced Auditory Serial Addition Test

Change in performance on the cognitive domain of working memory as measured with Backward Digit Span

Time Frame: Pretest, 6 months, and 12 months

Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Backward Digit Span

Change in performance on the cognitive domain of processing speed as measured with the Stroop Color Test

Time Frame: Pretest, 6 months, and 12 months

Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Stroop Color Test

Change in performance on the cognitive domain of executive function as measured with the Flanker test.

Time Frame: Pretest, 6 months, and 12 months

Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on the Flanker test.

Change in performance on the cognitive domain of executive function as measured with Matrix Reasoning.

Time Frame: Pretest, 6 months, and 12 months

Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Matrix Reasoning.

Change in performance on the cognitive domain of executive function as measured with Stroop Interference

Time Frame: Pretest, 6 months, and 12 months

Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Stroop Interference.

Change in performance on the cognitive domain of executive function as measured with Dimensional Change Card Sort

Time Frame: Pretest, 6 months, and 12 months

Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Dimensional Change Card Sort

Change in performance on the cognitive domain of memory as measured with the Picture Sequence test

Time Frame: Pretest, 6 months, and 12 months

Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Picture Sequence test.

Change in performance on the cognitive domain of attention as measured with the Forward Digit Span test

Time Frame: Pretest, 6 months, and 12 months

Change in attention will be assessed by comparing post-, mid-, and pre-test performance on the Forward Digit Span

Change in performance on the cognitive domain of working memory as measured with List Sort Working Memory

Time Frame: Pretest, 6 months, and 12 months

Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the List Sort Working Memory

Change in performance on the cognitive domain of working memory as measured with Spatial Working Memory

Time Frame: Pretest, 6 months, and 12 months

Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Spatial Working Memory

Change in performance on the cognitive domain of processing speed as measured with the Wechsler Adult Intelligence Scale (WAIS-IV) Digit Symbol Task

Time Frame: Pretest, 6 months, and 12 months

Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Wechsler Adult Intelligence Scale (WAIS-IV) Digit Symbol Task

Change in performance on the cognitive domain of executive function as measured with Trail Making Test Interference

Time Frame: Pretest, 6 months, and 12 months

Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Trail Making Test interference.

Change in performance on the cognitive domain of memory as measured with the Auditory Verbal Learning Test.

Time Frame: Pretest, 6 months, and 12 months

Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Auditory Verbal Learning Test.

Change in performance on the cognitive domain of processing speed as measured with the Trail Making Test A

Time Frame: Pretest, 6 months, and 12 months

Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Trail Making Test A

Change in performance on the cognitive domain of processing speed as measured with the Stroop Word Test

Time Frame: Pretest, 6 months, and 12 months

Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Stroop Word Test

Secondary Outcomes

  • Change in cardiorespiratory fitness(Pretest, 6 months, and 12 months)
  • Change in brain activity (resting-state connectivity)(Pretest and 12 months)
  • Change in brain morphology (whole brain and hippocampal volumes)(Pretest and 12 months)
  • Change in blood biomarkers (BDNF, irisin, IGF-1, glucose, insulin, TNF-⍺, serum amyloid protein (SAP), albumin, ApoE and ⍺-2 macroglobulin)(Pretest and 12 months)

Study Sites (1)

Loading locations...

Similar Trials